- Home
- TOPS vs KALA Comparison
TOPS vs KALA Comparison
Compare TOPS & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOPS
- KALA
- Stock Information
- Founded
- TOPS 2000
- KALA 2009
- Country
- TOPS Greece
- KALA United States
- Employees
- TOPS N/A
- KALA N/A
- Industry
- TOPS Marine Transportation
- KALA Biotechnology: Pharmaceutical Preparations
- Sector
- TOPS Consumer Discretionary
- KALA Health Care
- Exchange
- TOPS Nasdaq
- KALA Nasdaq
- Market Cap
- TOPS 27.2M
- KALA 26.2M
- IPO Year
- TOPS 2004
- KALA 2017
- Fundamental
- Price
- TOPS $5.95
- KALA $7.14
- Analyst Decision
- TOPS
- KALA Strong Buy
- Analyst Count
- TOPS 0
- KALA 3
- Target Price
- TOPS N/A
- KALA $14.00
- AVG Volume (30 Days)
- TOPS 18.2K
- KALA 198.2K
- Earning Date
- TOPS 08-08-2025
- KALA 08-05-2025
- Dividend Yield
- TOPS N/A
- KALA N/A
- EPS Growth
- TOPS N/A
- KALA N/A
- EPS
- TOPS 1.09
- KALA N/A
- Revenue
- TOPS $86,127,000.00
- KALA N/A
- Revenue This Year
- TOPS $9.90
- KALA N/A
- Revenue Next Year
- TOPS N/A
- KALA N/A
- P/E Ratio
- TOPS $5.58
- KALA N/A
- Revenue Growth
- TOPS 3.83
- KALA N/A
- 52 Week Low
- TOPS $5.00
- KALA $2.92
- 52 Week High
- TOPS $11.47
- KALA $11.20
- Technical
- Relative Strength Index (RSI)
- TOPS 46.80
- KALA 59.52
- Support Level
- TOPS $5.91
- KALA $5.35
- Resistance Level
- TOPS $6.36
- KALA $8.49
- Average True Range (ATR)
- TOPS 0.36
- KALA 0.81
- MACD
- TOPS 0.02
- KALA 0.17
- Stochastic Oscillator
- TOPS 18.92
- KALA 57.01
About TOPS TOP Ships Inc.
TOP Ships Inc owns tanker vessels throughout the world. The Company is an international owner and operator of modern, fuel-efficient eco tanker vessels focusing on the transportation of crude oil, petroleum products (clean and dirty), and bulk liquid chemicals. It generates revenue from the Time Charter agreements.
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.